Therefore, targeting neoantigens by NA-iPSC cancer vaccines in combination with RT remarkably increases the frequencies of neoantigen-specific CD8+ T cells to recognize tumor cells for cell killing, demonstrating impressive therapeutic benefits of NA-iPSC cancer vaccines for RT treatment. This evidence concerns the gene CD8A and neoplasm.